Coleman, S.

March 15, 2023
The Payer License Agreement, or “Netflix Model,” for Hepatitis C Virus Therapies Enables Universal Treatment Access, Lowers Costs and Incentivizes Innovation and Competition
Summary High unit prices of treatments limit access. For epidemics like that of hepatitis C virus (HCV), reduced treatment access increases prevalence and incidence, making the infectious disease increasingly difficult to manage. The objective of the current study was to construct and test an alternative pricing model, the Payer License Agreement (PLA), and determine whether […]

Read More
November 12, 2020
Strategies to eliminate hepatitis C in Croatia, a modelling study
Summary Background Since a 2016 analysis on the epidemiology and disease burden of HCV in Croatia, the HCV treatment paradigm has shifted substantially. Fibrosis restrictions were removed, and the number of patients treated tripled. With these encouraging changes to policy and practice, an updated analysis was completed to guide resource allocation and a national strategic […]

Read More
January 16, 2020
Global prevalence of hepatitis C virus in children in 2018: a modelling study
Summary Background Hepatitis C virus (HCV) prevalence estimates for adults and high-risk groups have been widely published, but the disease burden in children is poorly understood. Direct-acting antiviral drugs, which are considered to be highly effective curative therapies for HCV, are now approved for paediatric patients as young as 3 years. Reliable prevalence estimates for […]

Read More